Regeneron Pharmaceuticals Inc. buy PapaSmurf
Summary
This prediction ended on 19.12.19 with a price of €335.35. The BUY prediction by PapaSmurf finished with a performance of 25.13%. PapaSmurf has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | 2.813% | 2.813% | 30.574% | 120.343% |
iShares Core DAX® | 4.015% | 2.971% | 16.492% | 19.144% |
iShares Nasdaq 100 | 2.755% | 0.503% | 40.029% | 50.636% |
iShares Nikkei 225® | -0.826% | -5.057% | 14.566% | 2.379% |
iShares S&P 500 | 2.330% | 0.720% | 30.194% | 44.181% |
Comments by PapaSmurf for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren